Neurosalience
Early detection of dementia for decreasing further patient related costs and increasing the quality of life of patients.
Early detection of dementia for decreasing further patient related costs and increasing the quality of life of patients.
Neurosalience, founded in 2020 and headquartered in the United Kingdom, is a health care startup with the goal of enabling the early detection of dementia through MRI scans. The company's slogan, "Early detection of dementia for decreasing further patient related costs and increasing the quality of life of patients," encapsulates their mission. Their innovative tool not only identifies dementia at an early stage but also has potential for expansion to CT scans. This technology holds the promise of reducing patient-related expenses while simultaneously enhancing the quality of life for those affected by dementia. Neurosalience's progress has garnered the attention of investors, with their most recent €10.00K grant investment coming from Prototron on 29 January 2021.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | €10.00K | 1 | Prototron | 29 Jan 2021 |
No recent news or press coverage available for Neurosalience.
We care about your data, and we'd love to use cookies make your experience better.
